Islet transplantation is a potential cure for diabetes. However, allotransplant rejection severely limits its clinical application. In this study, we sought to transfect rat islets with an adenoviral vector containing the viral IL-10 (vIL-10) gene and examine its efficacy in preventing graft rejection. The immunosuppressive effect of vIL-10 is reported but its efficacy is somehow debatable in transplantation model. vIL-10 transfected islets were transplanted into streptozotocin-induced diabetic rats. Blood glucose, serum vIL-10 concentration, graft histology, and graft cytokine expression were used to monitor graft function up to day 21 after transplantation. Transfected islets released a large amount of vIL-10 protein without affecting their viability and functional integrity. When we transplanted the transfected islets into allogeneic hosts, the survival of grafted islets was not significantly increased. However, the combined use of vIL-10 and subtherapeutic doses of CsA (cyclosporine) significantly prolonged graft survival beyond that achieved with either agent alone (p < 0.001). vIL-10 and CsA-treated rats contain high level of vIL-10 in serum, which is evidenced by the inhibition of allogeneic mixed lymphocyte reaction (MLR). Histological analysis additionally revealed the presence of viable islets up to 21 days. IL-10 mRNA expression in grafted liver was higher and IFN-γ mRNA was lower in vIL-10 and CsA-treated animals, compared with other groups. The synergistic effect of this combination therapy is potentially correlated with the induction of inhibitory cytokine secretion and downregulation of proinflammatory cytokine secretion from host cells.
INTRODUCTION
regard to Th2-like immunity represents a reasonable therapeutic strategy for type 1 diabetes. On the basis of this theory, a number of immunomodulatory approaches Type 1 diabetes mellitus is an autoimmune disorder in which the insulin-producing cells of pancreatic islets have been explored over the past decade. These studies display credible potential for improving the outcome of are selectively destroyed (21) . The recent success of clinical islet transplantation has been limited by the re-islet transplantation and preventing type 1 diabetes (25). Viral interleukin 10 (vIL-10) expressed by the Epstein-quirement for large masses of islets to achieve complete graft function and insulin independence (12, 26) . Several Barr virus (EBV) gene, BCRF1, is highly homologous to mouse and human interleukin-10 (IL-10) (13, 20, 29) . factors reduce islet viability or impair islet function, and contribute to the high rate of rejection generally observed
The vIL-10 protein shares several biological properties with its murine and human counterparts, including cyto-in transplant recipients. Notably, the stress associated with islet isolation, purification, and culture, as well as kine synthesis inhibitory factor activity (8) . It impairs the function of antigen presenting cells by downregulat-hypoxia and nonspecific inflammation in the transplant microenvironment, negatively influences islet graft sur-ing the expression of major histocompatibility complex (MHC) class II, costimulatory (CD40, CD80, and CD86) vival (12) . These nonspecific inflammation reactions may trigger the immune system, and lead to allo-and or adhesion molecules (intercellular), and inhibiting the production of Th1-differentiating cytokines, particularly autoimmune responses. Recent reports suggest that immunological imbalance of the CD4 + T helper (Th) cell interferon (IFN)-γ and IL-12 (9, 10, 27) . These functions constitute important components of the anti-inflamma-response-specifically, increase in cytotoxic Th1 typeresults in the elimination of insulin-secreting pancreatic tory and immunosuppressive effects of IL-10. Unlike mammalian IL-10, vIL-10 does not stimulate thymo-cells (18) . Hence, fine-tuning the immune system with 610 KIM ET AL. cytes, B cells, or mast cells (8, 13, 28) . Several studies free conditions with a 12-h light/dark cycle and had free access to food and water. Care and handling of animals confirm the role of the transfected IL-10 gene in infectious diseases, inflammatory diseases, cancer, transplan-was carried out in accordance with the regulations of Animal Facilities. Recipients were rendered diabetic by tation, and autoimmune diseases (19) . Therapeutic effects of viral and cellular IL-10 gene transfer have been a single injection of streptozotocin (35 mg/kg, Sigma, St. Louis, MO) before transplantation. experimentally confirmed in transplantation (13, 24) , and autoimmune diseases, such as experimental arthritis (2, Islet Isolation and Culture 17), diabetes of nonobese diabetic (NOD) mice (23, 32) , After inducing death of rats with CO 2 , the pancreas and uveoretinitis (7) .
was exposed and injected with 1000 U/ml Hank's bal-Success in obtaining grafts transfected to express imanced salt solution (HBSS) containing collagenase (Sigma) munosuppressive molecules locally for inducing transvia the pancreatic duct. Pancreatic tissue was surgically plant tolerance is currently limited, despite increasing removed, and incubated at 40°C in a water bath. After interest in the field. The gene delivery system and time 26 min of incubation, digestion kinetics was rapidly are most critical. Various transplant models show that slowed down by addition of cold HBSS supplemented ex vivo modification of allogeneic grafts or systemic apwith 5% FBS. Digested pancreatic tissue was mechaniplication via gene transfer techniques with recombinant cally disrupted by filtering through a mesh (400 µm pore vectors (e.g., retrovirus or adenovirus) leads to signifisize), and washed with cold HBSS supplemented with cantly prolonged allogeneic transplant survival (1,3,24). 5% FBS. Islets were purified by discontinuous density Among these, the adenoviral vector is one of the most gradient centrifugation using Ficoll (Sigma), counted, effective systems in human pancreatic endocrine cells and scored for size using an algorithm for the calculation for ex vivo gene transfer (16) . However, recent study of islet equivalent number. Before transplant, islets were show that ex vivo gene transfer of vIL-10 failed to procultured overnight in RPMI-1640 medium supplemented long graft survival in autoimmune diabetic BB rats (14) .
with 10% FBS at 37°and 5% CO 2 . One of the major problems in adenoviral vector-mediated gene transfer to islets is the host immune response,
Preparation of Adenoviral Vectors which causes direct damage to transfected cells and loss
The adenoviral vectors, dl324/∆E1/GFP (Ad-GFP) of transgene expression within 14 to 21 days (6). Anand dl324/∆E1/vIL-10 (Ad-vIL-10), contain expression other problem is that expression of genes in the graft cassettes encoding GFP and rat vIL-10 in lieu of viral requires 1-2 days after transplantation, while significant E1A and the majority of the ElB region, respectively. T-cell activation, inducing rejection, may occur even be-
The resulting virus constructs are replication defective. fore gene expression reaches critical levels (22) . An im-Both Ad-vIL-10 and Ad-GFP were grown to a high titer, munosuppressive agent, such as CsA, administered at purified once through a CsCl cushion, and again on a the time of gene transfer and transplantation may reduce continuous CsCl gradient. Titers of purified virus stocks the function of the immune system during this early apwere measured by plaque formation on 293 cells. plication period; thus, it would allowed for expression of immunoregulatory genes before T-cell activation is Assessment of Transfection Efficacy initiated. In addition, CsA may prolong expression of Isolated islets in media were cocultured in 24-well the transfected gene through inhibition of the adenoviplates with Ad-GFP and Ad-vIL-10 at MOI (multiplicity ral-directed immune response. In this study, we investiof infection, infection units/islet) of 5, 10, 50, and 100 gated the effects of adenoviral infection on islet viability for 2 h. After incubation, transfected islets were washed and function at different time points after transfection.
with fresh medium and transferred to a 24-well plate Additionally, we examined the efficacy of ex vivo vILwith 1 ml fresh medium in each well. GFP expression 10 gene transfer via adenoviral vectors in combination by transfected islets was determined by confocal microswith subtherapeutic doses of CsA administered at the copy. Quantitative analysis of transfection was pertime of transplantation in a rat islet allograft model. formed on islets by acquiring 10,000 cells per condition using a FACScan (FACSCalibur, Becton-Dickinson,
MATERIALS AND METHODS
San Diego, CA) to determine the percentage of cells ex-Experimental Animals pressing GFP. All experiments were performed in tripli-Male Lewis (LE; RT1 1 ) rats and Fisher rats under cate for reproducibility. Results are expressed as means 8-10 weeks of age were used as donors and recipients, with standard deviation. respectively. Fisher rats were purchased from Charles Detection of Secreted vIL-10 Using ELISA River Japan, Inc. (Kanagawa, Japan). Lewis rats were bred and maintained at Asan Medical Center Animal Ex vivo and in vivo vIL-10 production was detected with ELISA. Experiments were performed using a hu-Facilities. All rats were housed under specific pathogen-man IL-10 detection kit (Endogen, Cambridge, MA) that and a diaminobenzidine peroxidase substrate kit (Vector Laboratories, Burlingame, CA). recognizes vIL-10, in accordance with the manufacturer's recommendations.
Mixed Lymphocyte Reaction (MLR) Splenic lymphocytes were isolated from normal Lewis Mixed Lymphocyte Islet Culture (MLIC) rats by centrifugation on Ficoll density gradients (Histo-Allogeneic splenocytes (5 × 10 5 ) were cultured with paque 1077, Sigma). A total of 100 µl cells (5 × 10 6 50 isolated Lewis islets in a final volume of 100 µl of cells/ml) were mixed with an equal volume of irradiated RPMI-1640 medium containing 10% FBS per well, ei-(20 Gy) allogeneic splenocytes on 96-well U-bottom ther in the presence or absence of CsA (300 ng/ml; Sanculture plates (NUNC, Roskilde, Denmark). Mixed cells dimmune; Novartis). Lymphocytes or islets cultured were cultured for 3 days with 1:100 diluted serum from alone were used as controls. In brief, lymphocytes and recipient or normal rats in a humidified CO 2 incubator islets were cultured for 96 h at 37°in 5% CO 2 . T-cell (5% CO 2 , 37°C). Each well was pulsed with 1 µCi of proliferation was determined using a colorimetric immu- At 1, 3, 5, 7, 14, and 21 days after transplantation, Assessment of Islet Viability and Function In Vitro liver samples were snap-frozen in liquid nitrogen and stored at −80°C until use. Total RNA was isolated using The total islet number was determined on the basis TRIzol (Invitrogen, Cergy Pontoise, France), and 10 µg of size and area as the number of islet equivalents (IEQ), of mRNA was reverse-transcribed using the reversedefined as a cell conglomerate 150 µm in diameter.
transcriptase kit (Bioneer, Daejeon, South Korea). Rat Viability was determined by calculating the number of primer sequences for IL-2, IL-10, TGF-β1, and GAPDH dithizone-stained cells. A glucose-stimulated insulin sewere as follows: glyceraldehyde-3-phosphate dehydrocretion assay was used to assess β-cell function in ungenase (GAPDH) sense, 5′-TCA TGA CCA CAG TCC transfected, Ad-GFP-transfected, and Ad-vIL-10-trans-ATG CCA-3′ and antisense, 5′-GGG AGT TGC TGT fected islets. Islets were incubated for 1 h in KHBB TGA AGT CAC-3′; IL-2 sense, 5′-TTG CAC TGA CGC buffer containing either basal (0.03%) glucose or stimu-TTG TCC TCC TTG TCA ACA-3′ and antisense, 5′lated (0.3%) levels of glucose, and the amount of insulin CCA TCT CCT CAG AAA TTC CAC CAC AGT TGCreleased was measured.
3′; IL-10 sense, 5′-GGT GAC AAT AAC TGC ACC CAC-3′ and antisense, 5′-GTG TCA CGT AGG CTT Islet Transplantation CTA TGC-3′; TGF-β1 sense, 5′-GCC TCC GCA TCC Transfected islets were transplanted into recipient rat CAC CTT TG-3′ and antisense, 5′-GCG GGT GAC TTC livers via the portal vein. Animals were divided into four TTT GGC GT-3′. PCR was performed at 95°for 5 min, experimental groups. Group 1 received donor islets withfollowed by 30 cycles at 95°for 30 s, 60°for 45 s, and out transfection, group 2 was treated with CsA (5 mg/ 72°for 1 min. Amplified products were analyzed on a kg) for 2 weeks, group 3 received donor islets transfec-1-2% agarose gel. Bands were quantified with the Bioted with Ad-vIL-10, and group 4 was treated with both Rad Quantity one program (Bio-Rad, Hercules, USA). Ad-vIL-10 and 5 mg/kg of CsA for 2 weeks. Each ex-GAPDH was applied as an endogenous control to norperimental group comprised 4-5 animals. Graft function malize RNA amounts. was monitored by daily measurement of blood glucose during the first 2 weeks, and at least twice thereafter.
Statistical Analysis Islet rejection was recorded if blood glucose values were
The significance of differences between groups was higher than 200 mg/dl on 2 consecutive days.
analyzed with the Student's t-test. Data were expressed as means ± SE. Differences were considered statistically Immunohistochemistry significant at values of p < 0.05. The grafted liver was removed, fixed in formalin, em-RESULTS bedded in paraffin, and sectioned. Liver sections were
Effect of Viral Dose on Transfection Efficacy incubated with mouse anti-rat insulin (BD Bioscience, and Viability NJ, USA), mouse anti-rat CD4, CD8 alpha (Serotec, Oxford, UK), or mouse anti-rat RT1B antibody (BD Bio-Because adenovirus infection damages islets and interferes with their biologic function (30), we determined science) with a Vectastain ABC peroxidase standard kit the effects of varying viral doses on transfection effi-ted islets were used as the control for determination of endogenous vIL-10 produced from rat islets. Transfected ciency. Confocal images of rat islets transfected with Ad-GFP at MOI of 5, 10, 50, or 100 were analyzed on islets secreted significant amounts of vIL-10 into the culture medium up to 7 days, which increased with viral posttransfection day 3 (Fig. 1) . Islets displayed green fluorescence, indicative of transfection success. GFP-dose and incubation time posttransfection, compared to nontransfected islets (Fig. 2C ). Next, we determined expressing islets were proportional to the viral dose and incubation time after transfection. We additionally deter-whether vIL-10 and CsA have additive or synergistic effects. A CsA concentration of 300 ng/ml was em-mined the effects of incubation time of islets with adenoviral vectors on transfection efficacy. The intensity ployed, because this was the highest single dose that induced no adverse effects. Inhibition of allo-MLIC was and number of GFP-positive islets were proportional to incubation time, with 24 h being the highest time point significantly higher upon treatment with a combination of vIL-10 and CsA than either agent alone, implying examined (2, 4, 8, 12, 24 h; data not shown). Because prolonged incubation of islets with adenoviral vector is synergistic activity (Fig. 2D ).
detrimental to islet function, in subsequent experiments
Effect of vIL-10 Gene Transfer and CsA Treatment 2 h and MOI of 10 were employed as the optimal time on Rat Islet Allograft Survival and dose for islet transfection, respectively, in terms of both transfection efficiency and viability of islets.
To evaluate the effects of vIL-10 on allograft survival, Ad-vIL-10-transfected islets were injected into the Glucose-Stimulated Insulin Release, vIL-10 portal vein. The mean graft survival of nontreated and Secretion, and Mixed Lymphocyte Islet Culture vIL-10-treated groups was 5 and 6 days, respectively.
in Transfected Islets
Treatment with vIL-10 alone induced no effects on graft survival. Additional experiments were performed to de-To determine whether insulin secretion is adversely affected by adenovirus infection, in vitro islet function termine the effects of administering CsA at subtherapeutic doses in collaboration with vIL-10 transfection. The tests were performed by static incubation of both Ad-vIL-10 transfected and nontransfected control rat islets mean graft survival of rats receiving a subtherapeutic dose of CsA (5 mg/kg) was 7 days, similar to control, with glucose. In all groups, the amount of insulin released was elevated after incubation of islets with glu-while that of animals treated with both vIL-10 and CsA was 29.3 days (Fig. 3A, Table 1 ). cose. The data clearly indicate that islet function is maintained over this time period (Fig. 2B) . Thus, Ad-Serum Concentrations of vIL-10 in the Recipient Rats vIL-10 does not alter the islet β-cell physiologic response to glucose challenge. Secreted vIL-10 from Serum concentrations of vIL-10 were monitored until 21 days after transplantation. As shown in Figure 4A , transfected islets was measured in the supernatant at posttransfection days 1, 3, 5, 7, 14, and 21. Nontransfec-vIL-10 serum levels were maximum at day 1 after trans- plantation in vIL-10 alone (457.3 ± 11.7 pg/ml), and tal vein (Fig. 3B ). Islets were viable in the livers of rats receiving vIL-10 and a short course of CsA, and normal vIL-10 and CsA-treated groups (590.7 ± 8.1 pg/ml). The vIL-10 levels between the two groups were significantly glucose levels were maintained for more than 21 days after transplantation. Insulin was generated from these different throughout the posttransplant period (p < 0.05). However, vIL-10 was not detected in nontreated and islets, as evident from anti-insulin antibody staining. Histological examination of the grafted liver revealed CsA-treated rats. Serum was obtained from nontreated, CsA-treated, vIL-10-treated, or vIL-10 and CsA-treated mild cellular infiltration around islets on day 1 in all groups. In nontreated and vIL-10-treated groups, cell in-recipients on day 5 after grafting, and added to the allogeneic MLR. [ 3 H]Thymidine incorporation was signifi-filtrates increased progressively from days 3 to 5. No differences in CD4 + T-cell infiltrates were observed cantly decreased by the serum of recipients treated with both vIL-10 and CsA compared to serum of the control among the groups. However, the number of CD8 + T cells was significantly greater in the nontreated group group (Fig. 4B ). Neutralizing antibodies against vIL-10 treatment restored allogeneic MLR suppression. Thus, than in CsA-treated, vIL-10-treated, and vIL-10 plus CsA-treated groups on day 5 (Fig. 5 ). The only clear combined vIL-10 gene transfer and CsA treatment induces a high level of vIL-10 in serum, which is able to difference between the combined vIL-10 and CsAtreated long-surviving grafts and rejecting grafts (non-inhibit allogeneic MLR. treated, vIL-10 alone, CsA alone) was the presence of Cellular Infiltration in Islet Allografts of vIL-10 Gene higher numbers of CD4 + , CD8 + , and MHC II + cells in Transfer and CsA Treatment the former group on day 21. Rejection was significantly correlated with the number of CD4 + /CD8 + cells Immunohistological analyses confirmed insulin expression in transfected islets transplanted under the por-in grafts. Graft survival, following islet allograft in four groups. Group 1: no treatment; group 2: CsA (5 mg/kg); group 3: Ad-vIL-10; group 4: Ad-vIL-10 + CsA (5 mg/kg). *p < 0.001, group 4 versus groups 1, 2, 3. (B) Immunohistochemical staining of insulin in liver tissue from rats transplanted with islets at days 1, 5, 7, 14, and 21 after transplantation. Nontransfected islet cells were used as the control. Magnification ×400.
Expression of Cytokines in Grafted Livers of vIL-10 DISCUSSION and CsA-Treated Animals
Adenoviral vectors can be used to achieve efficient gene transfer in different animal models and cell types, Quantitative RT-PCR analysis of cytokine mRNA levels in grafts at 5 days revealed a marked decrease in including nondividing cells. One of the major limitations of these vectors is the transient nature of transgene ex-INF-γ transcript levels in Ad-vIL-10 plus CsA-treated rats, compared to control and Ad-vIL-10-treated rats.
pression. Previous studies with adenoviral vectors show that transgene expression is lost or greatly diminished Moreover, in animals receiving both vIL-10 and CsA, the IL-10 mRNA level was higher than that in other after 30 days (11, 15) . The limited duration of transgene expression after adenoviral-mediated gene transfer may groups. These findings imply that the combination therapy leads to a decrease in the expression of Th1 cyto-be due to either immune-or nonimmune-mediated mechanisms. Because CsA was used to suppress early T-cell kine (INF-γ) within the grafts of recipients and elevated Th2 cytokine levels (Fig. 5) .
activation, this strategy is effective in adenoviral vector experiments. In the present investigation, CsA adminis-basal level on day 21 after transplantation. A low dose of CsA (5 mg/kg) provides sufficient immunosuppres-tered at a subtherapeutic dose (5 mg/kg) at the time of transplantation acted synergistically with vIL-10 to en-sion during the first 2 days following transplantation to protect the islet graft until adenovirus transfection deliv-hance allograft survival. In addition, rats treated with CsA plus vIL-10 exhibited an abrupt rise in serum vIL-ers effective vIL-10 levels (33) . The higher serum levels of vIL-10 detected in the combination group suggest that 10 levels that peaked on day 1, and then declined to the CsA enhances gene expression by preventing antivirus tent with the in vivo rejection reaction. Thus, CsA and vIL-10 act synergistically in blocking the initiation of immune responses.
Previous studies of transplantation of vIL-10 trans-antigen presentation and immune activation, thus prolonging graft survival. genic mouse hearts expressing high levels of vIL-10 failed to prolong survival and elicited massive infiltra-
The immune response to adenoviral vectors can induce inflammation and loss of transgene expression in tion of inflammatory cells in fully major histocompatibility complex mismatched recipient littermates (1). In transfected tissues (5). Recently, Yap et al. (31) reported that CsA prolongs the duration of Ad-βgal gene expres-our study, the inability of Ad-vIL-10 to prolong islet graft survival was possibly due to the limited time of sion and decreases inflammation induced by viral vectors in rat cardiac syngeneic and allogeneic transplanta-transgene expression and massive infiltration of MHC class II + , CD4 + , or CD8 + T lymphocytes into the graft.
tion. The group suggests that CsA prolongs transgene expression due to reduction of host immune responses In addition, our in vitro data show that expression of transfected genes in allografts did not reach the maximal against adenoviral vectors. This prolonged transgene expression by CsA possibly explains the synergistic im-level until day 2 posttransplantation. Thus, it is likely that the acute rejection process is already initiated before mune suppressive effect observed in our experiments.
In summary, we demonstrate that Ad-vIL-10 can be the vIL-10 levels reach critical immunosuppressive levels, and IL-2 and IFN-γ transcripts are detected as early successfully delivered into islets using adenovirus vectors, and ex vivo transfer of the adenovirus-mediated as day 1 posttransplant in a rat model of acute allograft rejection (4). These may limit the effect of vIL-10, re-vIL-10 gene in combination with a short course of CsA therapy at subtherapeutic doses facilitates long-term sur-sulting in graft loss at day 6 in the vIL-10-treated group. Similarly, Beate Kuttler et al. reported that the local vival of islet grafts. CsA may be responsible for protecting grafts from alloimmune attack early after transplan-expression of vIL-10 also failed to prolong islet graft survival in autoimmune diabetic BB/OK rats (14) . How-tation, and thus, continuous expression of vIL-10 in collaboration with low doses of CsA prolongs graft sur-ever, our studies indicate that administration of a subtherapeutic dose of CsA at the time of transplant surgery vival. along with Ad-vIL-10 transfection significantly pro- alone. The mechanisms responsible for this enhanced allograft survival may result from immunosuppression REFERENCES during the early postoperative period by CsA. However,
